NCT01355003终止不适用
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 1,080
- 主要终点
- Number of participants with adverse events following any dose of vaccine
研究概览
简要总结
This study will collect safety information on the use of GARDASIL™ in the Philippines.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 9 Years 至 46 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Received GARDASIL™
排除标准
- 未提供
结局指标
主要结局
Number of participants with adverse events following any dose of vaccine
时间窗: At least 30 days following any vaccine dose
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)Neoplasms, Glandular and EpithelialPoliomyelitisWhooping CoughDiphtheriaTetanusNCT00337428Merck Sharp & Dohme LLC843
已完成
2 期
Study of Gardasil in Mid-Adult Males (MAM)Human PapillomavirusNCT01432574H. Lee Moffitt Cancer Center and Research Institute150
进行中（未招募）
4 期
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantAllogeneic Hematopoietic Stem Cell Transplant RecipientHematopoietic and Lymphoid Cell NeoplasmNCT03023631M.D. Anderson Cancer Center48
已完成
不适用
GARDASIL™ Vaccine Impact in Population Study (V501-033)Human Papillomavirus InfectionsNCT01077856Merck Sharp & Dohme LLC54,516
已完成
不适用
Immunogenicity and Safety of HPV Vaccine Gardasil in Young WomenSystemic Lupus ErythematosusNCT00786409University of Chicago27